You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Immune responses to pneumococcal polysaccharides at one month post-primary vaccination (primary ATP immunogenicity cohort): 22F-ELISA

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

  Clin group Com group
  N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC
(95% CI) (95% CI) (95% CI) (95% CI)
Vaccine serotypes       
Serotype 1 219 100 2.67 218 100 2.46
(98.3 – 100) (2.46 – 2.91) (98.3 – 100) (2.25 – 2.69)
Serotype 4 219 100 3.95 218 100 3.14
(98.3 – 100) (3.59 – 4.36) (98.3 – 100) (2.84 – 3.47)
Serotype 5 219 99.5 4.34 218 100 3.59
(97.5 – 100) (3.95 – 4.76) (98.3 – 100) (3.29 – 3.92)
Serotype 6B 219 96.3 1.31 218 93.6 1.23
(92.9 – 98.4) (1.16 – 1.48) (89.5 – 96.4) (1.07 – 1.41)
Serotype 7F 218 100 3.10 217 100 3.20
(98.3 – 100) (2.83 – 3.39) (98.3 – 100) (2.92 – 3.51)
Serotype 9V 219 100 3.34 218 100 3.14
(98.3 – 100) (3.03 – 3.69) (98.3 – 100) (2.83 – 3.49)
Serotype 14 219 99.5 5.13 218 100 4.74
(97.5 – 100) (4.54 – 5.79) (98.3 – 100) (4.23 – 5.32)
Serotype 18C 219 100 5.00 218 99.5 5.15
(98.3 – 100) (4.40 – 5.69) (97.5 – 100) (4.43 – 5.97)
Serotype 19F 219 99.5 6.69 218 99.5 6.96
(97.5 – 100) (6.04 – 7.41) (97.5 – 100) (6.26 – 7.73)
Serotype 23F 219 98.2 1.98 218 97.2 1.68
(95.4 – 99.5) (1.76 – 2.23) (94.1 – 99.0) (1.49 – 1.90)
Cross-reactive serotypes       
Serotype 6A 219 69.4 0.38 218 60.6 0.28
(62.8 – 75.4) (0.32 – 0.45) (53.7 – 67.1) (0.23 – 0.33)
Serotype 19A 219 61.6 0.27 218 54.6 0.23
(54.9 – 68.1) (0.23 – 0.31) (47.7 – 61.3) (0.20 – 0.27)
  1. ATP = according to protocol.
  2. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
  3. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
  4. N = number of infants with available results.
  5. 95% CI = 95% confidence interval.
  6. GMC = geometric mean concentration.
  7. % = percentage of infants with antibody concentrations or OPA titres above the specified cut-off.